Trial Profile
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Non alcoholic Steatohepatitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Oct 2023
Price :
$35
*
At a glance
- Drugs Obeticholic acid (Primary)
- Indications Fibrosis; Non-alcoholic steatohepatitis
- Focus Registrational; Therapeutic Use
- Acronyms REVERSE
- Sponsors Intercept Pharmaceuticals
- 24 Jun 2023 Results (from studies REGENERATE and REVERSE)assessing non-invasive tests to identify precirrhotic fibrosis due to NASH presented at the European Association for the Study of the Liver Congress 2023
- 30 Nov 2022 This trial has been completed in Poland, according to European Clinical Trials Database record.
- 20 Oct 2022 Status changed from active, no longer recruiting to completed.